최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of microbiology and biotechnology, v.21 no.12, 2011년, pp.1299 - 1305
Davami, Fatemeh (Biotechnology Research Center, Pasteur Institute of Iran) , Barkhordari, Farzaneh (Biotechnology Research Center, Pasteur Institute of Iran) , Alebouyeh, Mahmoud (Biotechnology Research Center, Pasteur Institute of Iran) , Adeli, Ahmad (Biotechnology Research Center, Pasteur Institute of Iran) , Mahboudi, Fereidoun (Biotechnology Research Center, Pasteur Institute of Iran)
An important modification of thrombolytic agents is resistance to plasminogen activator inhibitor-1 (PAI-1). In previous studies, a new truncated PAI-1-resistant variant was developed based on deletion of the first three domains in t-PA and the substitution of KHRR 128-131 amino acids with AAAA in t...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
American Heart Association. 2008. Heart Disease and Stroke Statistics. Accessible at http://www.americanheart.org/downloadable/ heart/1200082005246HS_Stats%202008.final.pdf.
Backliwal, G., M. Hildinger, S. Chenuet, S. Wulhfard, J. M. De, and F. M. Wurm. 2008. Rational vector design and multipathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res. 36: e96.
Baldi, L., D. L. Hacker, M. Adam, and F. M. Wurm. 2007. Recombinant protein production by large-scale transient gene expression in mammalian cells: State of the art and future perspectives. Biotechnol. Lett. 29: 677-684.
Baruah, D. B., R. N. Dash, M. R. Chaudhari, and S. S. Kadam. 2006. Plasminogen activators: A comparison. Vascul. Pharmacol. 44: 1-9.
Benavides Damm, T. and F. M. Wurm. 2010. Generation of the stable cell line for the production of theraputic proteins using the Piggy Back transposon for transgene delivery. Master Thesis Project.
Benchenane, K., J. P. Lopez-Atalaya, M. Fernandez-Monreal, O. Touzani, and D. Vivien. 2004. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27: 155-160.
Burck, P. J., D. H. Berg, M. W. Warrick, D. T. Berg, J. D. Walls, S. R. Jaskunas, et al. 1990. Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain. J. Biol. Chem. 265: 5170-5177.
Davami, F., S. Sardari, A. Majidzadeh, M. Hemayatkar, F. Barkhrdari, M. Omidi, et al. 2010. Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments. J. Biomed. Biotechnol. 2010: 108159.
Erickson, L. A., M. H. Ginsberg, and D. J. Loskutoff. 1984. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J. Clin. Invest. 74: 1465-1472.
Hemayatkar, M., F. Mahboudi, A. Majidzadeh, F. Davami, B. Vaziri, F. Barkhordari, et al. 2010. Increased expression of recombinant human tissue plasminogen activator in Leishmania tarentolae. Biotechnol. J. 5: 1198-1206.
Krishnamurti, C. and B. M. Alving. 1992. Plasminogen activator inhibitor type 1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Semin. Thromb. Hemost. 18: 67-80.
Krishnamurti, C., B. Keyt, P. Maglasang, and B. M. Alving. 1996. PAI-1-resistant t-PA: Low doses prevent fibrin deposition in rabbits with increased PAI-1 activity. Blood 87: 14-19.
Krishnamurti, C., G. D. Young, C. F. Barr, C. A. Colleton, and B. M. Alving. 1991. Enhancement of tissue plasminogen activatorinduced fibrinolysis by activated protein C in endotoxin-treated rabbits. J. Lab. Clin. Med. 118: 523-530.
Li, X. K., H. R. Lijnen, L. Nelles, H. B. Van, J. M. Stassen, and D. Collen. 1992. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood 79: 417-429.
Majidzadeh, A., V. Khalaj, D. Fatemeh, H. Mahdi, B. Farzaneh, A. Ahmad, and F. Mahboudi. 2010. Cloning and expression of functional full-length human tissue plasminogen activator in Pichia pastoris. Appl. Biochem. Biotechnol. 162: 2037-2048.
Mitsuyama, K., M. Sata, and S. Rose-John. 2006. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev. 17: 451-461.
Nordt, T. K. and C. Bode. 2003. Thrombolysis: Newer thrombolytic agents and their role in clinical medicine. Heart 89: 1358-1362.
Novick, D. and M. Rubinstein. 2007. The tale of soluble receptors and binding proteins: From bench to bedside. Cytokine Growth Factor Rev. 18: 525-533.
Paoni, N. F., B. A. Keyt, C. J. Refino, A. M. Chow, H. V. Nguyen, L. T. Berleau, et al. 1993. A slow clearing, fibrinspecific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb. Haemost. 70: 307-312.
Pennica, D., W. E. Holmes, W. J. Kohr, R. N. Harkins, G. A. Vehar, C. A. Ward, et al. 1983. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301: 214-221.
Pham, P. L., A. Kamen, and Y. Durocher. 2006. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol. Biotechnol. 34: 225-237.
Ranby, M., N. Bergsdorf, G. Pohl, and P. Wallen. 1982. Isolation of two variants of native one-chain tissue plasminogen activator. FEBS Lett. 146: 289-292.
Rubin, L. A., C. C. Kurman, M. E. Fritz, W. E. Biddison, B. Boutin, R. Yarchoan, and D. L. Nelson. 1985. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135: 3172-3177.
Shohet, R. V., S. Spitzer, E. L. Madison, R. Bassel-Duby, M. J. Gething, and J. F. Sambrook. 1994. Inhibitor-resistant tissuetype plasminogen activator: An improved thrombolytic agent in vitro. Thromb. Haemost. 71: 124-128.
Soleimani, M., F. Mahboudi, N. Davoudi, A. Amanzadeh, M. Azizi, A. Adeli, et al. 2007. Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae. Biotechnol. Appl. Biochem. 48: 55-61.
Sporri, B., M. Bickel, D. Dobbelaere, J. Machado Jr., and D. Lottaz. 2001. Soluble interleukin-1 receptor - reverse signaling in innate immunoregulation. Cytokine Growth Factor Rev. 12: 27-32.
Stettler, M., X. Zhang, D. L. Hacker, J. M. De, and F. M. Wurm. 2007. Novel orbital shake bioreactors for transient production of CHO derived IgGs. Biotechnol. Prog. 23: 1340- 1346.
Truelsen, T. and R. Bonita. 2003. Advances in ischemic stroke epidemiology. Adv. Neurol 92: 1-12.
Varley, J. and J. Birch. 1999. Reactor design for large-scale suspension animal cell culture. Cytotechnology 29: 177-205.
Wagner, O. F., C. de Vries, C. Hohmann, H. Veerman, and H. Pannekoek. 1989. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J. Clin. Invest. 84: 647-655.
Weaver, W. D. 1996. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Eur. Heart J. 17 Suppl F: 9-15.
Wurm, F. and A. Bernard. 1999. Large-scale transient expression in mammalian cells for recombinant protein production. Curr. Opin. Biotechnol. 10: 156-159.
Wurm, F. M. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22: 1393-1398.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.